文献速递其他结缔组织病

抗HMGCR肌病:新西兰疾病与疾病结局的种族差异观察

Anti-HMGCR myopathy: observed ethnic differences in disease and disease outcomes in New Zealand.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

在新西兰纳入35例波利尼西亚裔和48例新西兰欧洲裔抗HMGCR肌病患者,波利尼西亚裔患者发病年龄更小(中位数64 vs 71岁,P=0.009),随访期间肌酸激酶(CK)正常化比例更低(54.2% vs 79.2%,P=0.016),其余疾病表型与结局无显著差异。

要点

  • 波利尼西亚裔抗HMGCR肌病患者发病年龄中位数64岁,低于新西兰欧洲裔的71岁(P=0.009)。
  • 随访期间CK正常化比例波利尼西亚裔为54.2%,新西兰欧洲裔为79.2%(P=0.016)。
  • 其余疾病表型与结局指标在两组间无显著差异。

核心结论

  • 波利尼西亚裔除抗HMGCR肌病发病率更高外,发病年龄更年轻,且在相似随访期内接受治疗后CK正常化可能性更低。
  • 作者认为该群体疾病负担过重,应促使对服用他汀期间出现肌肉症状的波利尼西亚裔患者进行早期评估。

研究设计与样本

  • 基于免疫沉淀法抗HMGCR阳性识别91例抗HMGCR肌病患者,采用优先种族数据纳入35例波利尼西亚裔和48例新西兰欧洲裔患者。
  • 通过查阅临床记录获取疾病表型、治疗和结局信息。

主要发现

  • 波利尼西亚裔患者就诊时年龄较新西兰欧洲裔患者更年轻(中位数64 vs 71岁,P=0.009)。
  • 波利尼西亚裔患者随访期间CK正常化比例低于新西兰欧洲裔患者(54.2% vs 79.2%,P=0.016),控制随访时长后仍如此。
  • 未发现其他疾病表型或结局的显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) myopathy is an immune-mediated necrotizing myopathy strongly associated with statin use in adults. Polynesians have a higher incidence of anti-HMGCR myopathy in New Zealand (NZ), but ethnic differences in phenotype and outcome are not known. METHODS: Ninety-one patients with anti-HMGCR myopathy were identified based on anti-HMGCR positivity by immunoprecipitation assay. Prioritized ethnicity data were used to identify 35 Polynesian and 48 NZ European patients to include in the cohort. Clinical records were accessed and information on disease phenotype, treatment and outcome was obtained. RESULTS: Polynesian patients were younger than NZ European patients at presentation (median 64 vs 71 years P = 0.009). They were less likely to normalize their creatine kinase (CK) over the follow-up period (54.2% vs 79.2%, P = 0.016), even after controlling for length of follow-up. There were no other significant differences in disease phenotype or outcome found. CONCLUSION: In addition to having higher incidence of anti-HMGCR myopathy, Polynesians are affected at a younger age and are less likely to achieve normal CK levels despite treatment over similar follow-up periods. The disproportionate burden of disease in this group should prompt early assessment of a Polynesian patient who presents with muscle symptoms while on a statin.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Anderson H, Chow KL, O'Donnell J, et al. Anti-HMGCR myopathy: observed ethnic differences in disease and disease outcomes in New Zealand. Rheumatology (Oxford). 2025. PMID: 40515650. doi:10.1093/rheumatology/keaf338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。